Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety

 
• By Jessica Merrill
  
closed book
Pfizer and Lilly closed the book on tanezumab • Source: Alamy

More from New Products

More from Scrip